🇫🇷·Jan 1, 1970Investor
News 23 March, 2026 Sensorion reports six-month update from the Audiogene Phase 1/2 Trial of SENS-501 and advances GJB2-GT (SENS-601) toward first-in-human clinical development
Publisher
S
Sofinnova Partners
France
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Sofinnova Partners
- Region
- France
- Scope
- Investor
- Published
- January 1, 1970
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on sofinnovapartners.com
Leave the platform to read the original full article on the publisher site.
Source: Sofinnova Partners
Scope: Investor
Related coverage
More related coverage
McGill Faculty of Medicine News·13h ago
FMHS events and calls for submission
Pharmaceutical Executive·13h ago
Zepzelca Fails to Meet Main Goal of Phase III Lagoon Trial in Second-Line Small Cell Lung Cancer
OrthoPediatrics·13h ago
Pediatric Plating Platform™ | Hip (Trauma)
McGill Faculty of Medicine News·13h ago